Updated:
Bone Health Technologies
Bone Health Technologies markets Osteoboost, an FDA-cleared wearable for osteopenia that uses vibration therapy to slow bone loss in postmenopausal women.
Bone Health Technologies
Bone Health Technologies, operating through its Osteoboost platform, develops an FDA-cleared wearable device aimed at reducing bone density loss in postmenopausal women with osteopenia. The firm's website and public messaging focus on the Osteoboost device's regulatory clearance and clinical claims. The firm's strategy involves direct-to-consumer distribution of a prescription wearable device, representing a medical device commercialization approach within bone health. The Osteoboost device claims a reduction in vertebral bone density loss, a reduction in vertebral bone strength loss, and a reduction in hip bone density loss, based on clinical trial data presented on its website. The firm partners with clinics like Midi Health for educational webinars. The firm is based in Redwood City, CA. Information regarding the size of its team, specific investors, or additional office locations is not publicly available on its website. The firm announced an $8M funding round to expand access to its prescription wearable, as noted on its own news section. The firm's structural profile is defined by its transition from a venture-backed startup to a commercial-stage medical device company. Its focus on an FDA-cleared, direct-to-consumer wearable for bone density offers an alternative to traditional pharmaceutical interventions for osteopenia.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Redwood City
Corporate office
Redwood City, CA, United States
Sector focus
Frequently asked questions
What does Bone Health Technologies do?
Bone Health Technologies commercializes Osteoboost, a prescription wearable device that uses precision vibration therapy to reduce bone density loss in postmenopausal women with osteopenia. The company's website states the device is FDA-cleared and clinically proven to slow loss of bone strength and density in the spine and hip.
Is Osteoboost FDA-cleared or FDA-approved?
Osteoboost is marketed as FDA-cleared, which is the regulatory pathway for Class II medical devices, not the more rigorous premarket approval (PMA) required for Class III devices like implantable bone stimulators. The company claims its device is the first FDA-cleared wearable therapy specifically for osteopenia.
How does Bone Health Technologies generate revenue?
The firm sells its Osteoboost device directly to consumers with a valid prescription. The website does not disclose pricing tiers, insurance reimbursement status, or any institutional sales channels. Their commercialization model appears to blend direct-to-consumer outreach with partnerships for clinical education, such as their webinar collaboration with Midi Health.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: